| Continuing Education |
|
Continuing Medical Education Conference "A Review of the Most Recent Developments in Cancer Therapy" November 6th 2010 Doubletree Hotel by the Galleria ACCREDITATION AND CREDITS EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. EXCEL Continuing Education designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physician Assistants: AAPA accepts AMA Category 1 Credit™ from organizations accredited by the ACCME. Nurse Practitioners: AANP accepts AMA Category 1 Credit™ from organizations accredited by the ACCME. Nurses: EXCEL Continuing Education is accredited by the FL Board of Nursing Provider # 50-619 and designates this activity for 4 nursing contact hours. EDUCATIONAL OBJECTIVES Upon completion of this activity, you should be able to:
TARGET AUDIENCE / PROGRAM OVERVIEW / NEEDS ASSESSEMENT This live activity has been designed to meet the educational needs of healthcare providers who diagnose and treat patients with solid tumor malignancies including oncologists, hematologist, surgeons, radiation oncologists, nurse practitioners, and other HCPs who in the course of their practice may see or refer these patients. To bridge the gap between rsearch and patient care, this conference is an excellent opportunity to gain a better understanding of the recent advances and critical issues in oncology as well as new developments in scientific research and their potential impact on cancer care. Experts in the fields of melanoma, breast, lung and genitourinary cancers will focus on key findings with the potential to change practice. Participants will be provided with the necessary context to integrate the relevant information into their practices with a focus on patient-centered care. SUPPORTERS At press time, this activity is supported through educational grants from: GENENTECH BRISTOL MYERS SQUIBB IMCLONE SYSTEMS ![]() |